Development of a Model to Predict Progression Free Survival After Treatment With Erlotinib in E3503
- Assess mesenchymal and epithelial markers in tissues from patients with non-small cell
lung cancer treated with erlotinib hydrochloride on clinical trial ECOG-E3503.
- Determine the loss of epithelial markers (E-cadherin) and gain of mesenchymal markers
(vimentin/cytokeratin co-expression) in these patients.
- Assess whether mesenchymal and epithelial markers are predictive of progression-free
survival (PFS) of these patients.
- Identify a single nucleotide polymorphism profile via whole genome mapping and other
known biomarkers to predict PFS of these patients.
OUTLINE: Tissue samples are analyzed by whole genome mapping for single nucleotide
polymorphism (SNP) rate and by signal detection rate and by quantitative
immunohistochemistry for mesenchymal (vimentin/cytokeratin) and epithelial (E-cadherin)
marker transitions. After biomarker identification and gene mapping are complete, a model to
predict progression-free survival in these patients is developed.
PROJECTED ACCRUAL: A total of 137 samples will be accrued for this study.
Mesenchymal and epithelial markers
Jill Kolesar, PharmD
University of Wisconsin, Madison
United States: Federal Government